Tag - ZEAL

Developments

Zealand Pharma gets FDA priority review in congenital hyperinsulinism

The FDA granted priority review designation for Zealand Pharma’s (NASDAQ:ZEAL; CVR-no. 20045078) dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients seven days of age and older with...

August 30, 2023

Developments

Zealand Pharma acquires Encycle Therapeutics

Zealand Pharma (NASDAQ:ZEAL) of Denmark has acquired Encycle Therapeutics, a closely-held biotech company in Toronto, exploiting a unique platform technology that enables the rapid synthesis of macrocyclic peptides...

October 24, 2019

Tag - ZEAL

Zealand Pharma gets FDA priority review in congenital hyperinsulinism

Zealand Pharma acquires Encycle Therapeutics

General

More